Shares of Applied Therapeutics (APLT) surged 68.8% on Wednesday after it announced a regulatory update regarding the ongoing new drug application (NDA) review of APLT’s lead candidate, govorestat, for treating classic galactosemia.Per the press release, in a late-cycle review meeting with the FDA, the regulatory body communicated to Applied Therapeutics that it no longer requires the opinion of an Advisory Committee. The Advisory Committee meeting was previously tentatively scheduled for Oct. 9, 2024.APLT’s ...